UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000008507 |
|---|---|
| Receipt number | R000009998 |
| Scientific Title | A Phase II trial of DA-EPOCH And Rituximab with HD-MTX therapy for newly-diagnosed DLBCL with CD5 expression (PEARL5 study) |
| Date of disclosure of the study information | 2012/07/25 |
| Last modified on | 2021/07/30 09:03:09 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2012/07/23 21:55:56 | ||
| 2 | Update | 2013/03/01 16:59:58 | Institutions |
|
| 3 | Update | 2013/03/05 16:12:16 | Institutions |
|
| 4 | Update | 2013/05/27 11:03:19 | Institutions |
|
| 5 | Update | 2013/09/27 18:16:53 | Email Institutions |
|
| 6 | Update | 2013/12/16 18:50:05 | Institutions |
|
| 7 | Update | 2013/12/24 09:21:36 | Institutions |
|
| 8 | Update | 2014/01/06 09:05:54 | Institutions |
|
| 9 | Update | 2014/01/28 20:39:52 | Institutions |
|
| 10 | Update | 2014/03/03 14:11:59 | Key exclusion criteria Key exclusion criteria |
|
| 11 | Update | 2014/03/07 15:12:13 | Institutions |
|
| 12 | Update | 2014/06/28 10:10:56 | Institutions |
|
| 13 | Update | 2014/08/12 15:50:45 | Institutions |
|
| 14 | Update | 2014/10/06 18:32:50 | Organization Organization Category of Funding Organization |
|
| 15 | Update | 2014/12/26 10:17:00 | Institutions |
|
| 16 | Update | 2015/01/14 10:13:00 | Last follow-up date |
|
| 17 | Update | 2015/02/20 15:38:49 | Institutions |
|
| 18 | Update | 2015/02/25 17:57:01 | Institutions |
|
| 19 | Update | 2015/02/26 12:00:25 | Institutions |
|
| 20 | Update | 2015/03/02 19:14:42 | Institutions |
|
| 21 | Update | 2015/03/09 22:16:52 | Institutions |
|
| 22 | Update | 2015/04/03 12:56:03 | Institutions |
|
| 23 | Update | 2015/04/08 20:17:13 | Institutions |
|
| 24 | Update | 2015/04/16 09:16:33 | Institutions |
|
| 25 | Update | 2015/04/20 09:10:15 | Institutions |
|
| 26 | Update | 2015/07/13 18:28:39 | Institutions |
|
| 27 | Update | 2015/11/12 14:22:54 | Recruitment status |
|
| 28 | Update | 2016/11/25 09:19:50 | Name of primary person or sponsor Organization Organization Organization Category of Funding Organization |
|
| 29 | Update | 2016/11/25 09:36:08 | Interventions/Control_1 Interventions/Control_1 Key exclusion criteria |
|
| 30 | Update | 2018/01/25 09:17:02 | Category of Funding Organization |
|
| 31 | Update | 2019/01/24 14:25:38 | Institutions |
|
| 32 | Update | 2019/04/25 16:56:56 | Date of IRB Last follow-up date |
|
| 33 | Update | 2020/07/30 13:13:29 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address Last name of contact person Last name of contact person Zip code Address Organization Organization Address Address Tel |
|
| 34 | Update | 2020/07/30 13:14:42 | Publication of results Number of participants that the trial has enrolled |
|
| 35 | Update | 2021/07/30 09:03:09 | Recruitment status |
